Skip to main content
Quest Diagnostics

Humoral and Cellular Immune Responses Against SARS-CoV-2 Following Vaccination in Immunocompetent and Immunocompromised Cancer Populations

American Society for Microbiology

ASM Microbe 2023

Houston, TX, June 15-19 , 2023

Oral presentation: Humoral and Cellular Immune Responses Against SARS-CoV-2 Following Vaccination in Immunocompetent and Immunocompromised Cancer Populations

Authors:  Titova E, Kan VW, Shier K, Ponraj V, Starolis M, Kaufman HW, Ansari S, Lozy T, Goldgirsh K, Kim S, Pelliccia M, Mccutchen A, Megalla M, Gunning T, Ip A, Meyer WA, Perlin DS

Specialty: Infectious disease, COVID-19, Oncology

Related content

Conference Presentation
SARS-CoV-2 IGM Detection in Relation To Reactivity In 4 SARS-Cov-2 IGG Assays

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.